ABOUT US
ABOUT US
Our Mission
To improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC Discovery Engine.
Transforming the Future for Patients
Arvinas is singularly focused on developing new options for patients in need, pioneering a new class of medicines to target and degrade disease-related proteins.
For people living with cancers and other difficult-to-treat diseases, our approach has the potential to be transformative. Our proprietary PROTACs, or proteolysis-targeting chimeras, are designed to work by harnessing the body’s own natural protein disposal system to degrade and remove disease-causing proteins.
We Are Undeterred by “Undruggable”
We’ve developed a broad technology platform focused on high-value targets to deliver more potent therapies and address the majority of proteins that evade inhibition—including those that have been deemed “undruggable” by traditional approaches.
Our lead programs are currently focused on the receptors associated with prostate and breast cancers.
At Arvinas, we work every day to unlock the full potential of PROTACs, developing a robust pipeline and partnering with the world’s leading drug development companies to bring new possibilities where they are needed most.
Milestones in Scientific Discovery
- Arvinas creates its first blood-brain barrier-crossing PROTAC *
- Arvinas PROTAC AR degrader (bavdegalutamide) and PROTAC ER degrader (vepdegestrant) enter clinical studies
- First Phase 3 registrational study with vepdegestrant initiated
The agents mentioned above are currently under investigation; their safety and effectiveness have not yet been established
PROTAC (PROteolysis TArgeting Chimera); IND, investigational new drug; CTA, clinical trial authorization; AR, androgen receptor; ER, estrogen receptor; BCL6, B-cell lymphoma 6; LRRK2, leucine-rich repeat kinase 2
*Based on preclinical studies
